In This Section

Third AACR International Meeting Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application

In cooperation with the International Conference on Malignant Lymphoma (ICML)

In association with Blood Cancer Discovery

June 23-26, 2022
Westin Copley Place
Boston, Massachusetts

COVID-19 Guidelines and Requirements


Riccardo Dalla-Favera, Columbia University, New York, New York
Sonali M. Smith, University of Chicago, Chicago, Illinois


Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland*
Alexey V. Danilov, City of Hope National Medical Center, Duarte, California
Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, Texas
Ari M. Melnick, Weill Cornell Medical College / Cornell University, New York, New York
Teresa Palomero, Columbia University, New York, New York
Margaret A. Shipp, Dana Farber Cancer Institute, Boston, Massachusetts
Christian Steidl, BC Cancer, Vancouver, BC, Canada
Karin Tarte, University of Rennes, Rennes, France

* – ICML Representative

This third AACR lymphoma program will once again provide a unique forum for interactive discussion and brainstorming among basic scientists, translational researchers, clinical investigators, hematologists, radiotherapists, pediatric oncologists, pathologists, and patient-advocates about how recent advances and emerging areas of lymphoma research hold enormous potential for transforming clinical care. We hope attendees enjoy the highly interactive format which has generated productive discussions and launched new collaborations at previously programs that continue to move the field forward.

According to the latest data from the U.S. National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, non- Hodgkin lymphoma (NHL) is the seventh most common cancer in the United States with an estimated 81,560 new cases diagnosed in 2021 with an estimated 20,720 deaths in the U.S. along from NHL. Although lower in number than NHL, an estimated 8,830 new cases of Hodgkin lymphoma (HL) were diagnosed in the U.S. in 2021, with an estimated 960 deaths. Dramatic increases in the five-year survival rates for both NHL and HL over the past 50 years have resulted in these being considered success stories in terms of cancer survival. However, additional research and collaboration are needed in the early detection of these diseases and in the diagnosis and treatment of lymphoma to reduce the number of new cases in the U.S. and abroad. It is hoped that this meeting will provide a venue to address the global challenges and opportunities in lymphoma research.

In recent years, thanks to the ICML President, Dr. Franco Cavalli, the AACR has had the honor of being a collaborator with the hugely successful ICML conference on Advances in Malignant Lymphoma, held every other year since 1981, in Lugano, Switzerland. Because of the increasing number of AACR members working in lymphoma and related hematologic malignancies, and the rapid advances being made in this field, the AACR leadership has recognized the importance of holding this meeting series in the U.S. that will address the urgent professional and information needs of lymphoma researchers and clinicians residing in the U.S. and abroad. We look forward to building on the synergies that have resulted from the cooperation with our distinguished colleagues at the ICML. Please make plans to join colleagues in Boston for this exciting meeting.

Lead Supporter






Seattle Genetics

Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available